Dr Reddy’s Laboratories (RDY) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Dr. Reddy’s Laboratories reported a 17% year-over-year increase in revenue for the second quarter, reaching ₹80,162 million, driven by strong growth in global generics and emerging markets. Despite the rise in revenues, the company faced a decline in profit after tax attributable to equity holders, which fell by 15% year-over-year. The Board also approved a significant investment in its Russian subsidiary to support working capital needs, reflecting its ongoing commitment to strengthening core businesses and expanding market presence.
For further insights into RDY stock, check out TipRanks’ Stock Analysis page.
